Garg P K, Garg S, Degraff W G, Zalutsky M R, Mitchell J B
Department of Radiology, Duke University Medical Center, Durham, NC 27710.
Int J Radiat Oncol Biol Phys. 1992;22(3):593-6. doi: 10.1016/0360-3016(92)90884-k.
We have synthesized two 2-nitroimidazole derivatives and evaluated their hypoxic radiosensitization properties. The first, a 4-fluorobenzylamine conjugate of 2-nitroimidazole (PK-110), was designed so that it could also be labeled with the F-18 and used for positron emission tomographic imaging of hypoxia. The second, the L-phenylalanine methyl ester conjugate of 2-nitroimidazole (PK-130), was designed in an attempt to exploit amino acid transport channels to enhance drug transport into the tumor. The effects of these drugs (and SR-2508, for comparison) in vitro on the aerobic and hypoxic radiosensitivity of Chinese hamster V79 cells were evaluated using clonogenic assays. PK-130 and PK-110 at 0.1 and 1.0 mM were more efficient hypoxic cell radiosensitizers than obtained with 1.0 mM SR-2508. Marginal aerobic radiosensitization was observed for 1.0 mM treatment with PK-130 and PK-110, however, no aerobic radiosensitization was observed at 0.1 mM. Glutathione (GSH) depletion (less than 5% of control levels) by L-buthionine sulfoximine (BSO) further enhanced the SER for both PK-130 and PK-110 at 0.1 mM to 3.2 +/- 0.63 and 2.4 +/- 0.16, respectively. The results of this study encourage the in vivo tumor radiosensitization evaluation of PK-130 and PK-110.
我们合成了两种2-硝基咪唑衍生物,并评估了它们的乏氧放射增敏特性。第一种是2-硝基咪唑的4-氟苄胺共轭物(PK-110),其设计目的是还能用F-18进行标记,并用于乏氧的正电子发射断层显像。第二种是2-硝基咪唑的L-苯丙氨酸甲酯共轭物(PK-130),其设计目的是试图利用氨基酸转运通道来增强药物向肿瘤内的转运。使用克隆形成试验评估了这些药物(以及作为对照的SR-2508)在体外对中国仓鼠V79细胞需氧和乏氧放射敏感性的影响。0.1 mM和1.0 mM的PK-130和PK-110作为乏氧细胞放射增敏剂比1.0 mM的SR-2508更有效。用1.0 mM的PK-130和PK-110处理时观察到了轻微的需氧放射增敏作用,然而,0.1 mM时未观察到需氧放射增敏作用。用L-丁硫氨酸亚砜胺(BSO)使谷胱甘肽(GSH)耗竭(降至对照水平的5%以下)进一步增强了0.1 mM的PK-130和PK-110的增敏增强比(SER),分别达到3.2±0.63和2.4±0.16。本研究结果促使对PK-130和PK-110进行体内肿瘤放射增敏评估。